Provided by Tiger Fintech (Singapore) Pte. Ltd.

Recursion Pharmaceuticals, Inc.

4.71
+0.20004.43%
Pre-market: 4.790.0800+1.70%06:18 EST
Volume:24.53M
Turnover:114.12M
Market Cap:2.45B
PE:-2.64
High:4.77
Open:4.51
Low:4.46
Close:4.51
52wk High:12.36
52wk Low:3.79
Shares:520.64M
Float Shares:415.00M
Volume Ratio:0.54
T/O Rate:5.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7839
EPS(LYR):-1.6909
ROE:-91.06%
ROA:-42.20%
PB:2.34
PE(LYR):-2.79

Loading ...

Nvidia-Linked Shares Fall. CoreWeave Down over 12%; Applied Digital Down 8%; Nvidia, Innoviz, SoundHound AI Down Around 3%; Nebius Down 2%

Tiger Newspress
·
Yesterday

Will Recursion’s (RXRX) CEO Transition and Roche Milestone Mark a Turning Point for Its AI Strategy?

Simply Wall St.
·
Nov 09

Stock Track | Recursion Pharmaceuticals Plummets 7.16% as CEO Reports Share Disposal

Stock Track
·
Nov 07

Stock Track | Recursion Pharmaceuticals Plummets 7.16% as CEO Reports Share Disposal

Stock Track
·
Nov 07

Recursion Pharmaceuticals CEO Christopher Gibson Reports Disposal of Common Shares

Reuters
·
Nov 07

Recursion Pharmaceuticals: Q3 2025 Financial Highlights

TIPRANKS
·
Nov 06

Strong Financial Position and Strategic Leadership Drive Buy Rating for Recursion Pharmaceuticals

TIPRANKS
·
Nov 06

Stock Track | Recursion Pharmaceuticals Soars 5% Pre-Market on CEO Transition and $30M Milestone Achievement

Stock Track
·
Nov 05

Recursion Pharmaceuticals Announces New CEO Appointment

TIPRANKS
·
Nov 05

Recursion Pharmaceuticals Shares 5.4% Premarket After Q3 Revenue Miss

THOMSON REUTERS
·
Nov 05

Recursion Q3 revenue misses estimates, net loss widens

Reuters
·
Nov 05

Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q3 $0.36 Loss a Share, vs. FactSet Est of $0.38 Loss

MT Newswires Live
·
Nov 05

Recursion Pharmaceuticals Q3 EPS $(0.36) Misses $(0.31) Estimate, Sales $5.175M Miss $16.983M Estimate

Benzinga
·
Nov 05

Stock Track | Recursion Pharmaceuticals Plunges 5% Pre-Market on Weak Q3 Results and CEO Transition

Stock Track
·
Nov 05

Stock Track | Recursion Pharmaceuticals Plunges 5% Pre-Market on Weak Q3 Results and CEO Transition

Stock Track
·
Nov 05

Recursion Pharmaceuticals reports $30 million milestone payment and $785 million cash balance for Q3 2025

Reuters
·
Nov 05

Recursion Pharmaceuticals Inc: Q3 Total Revenue $5.2 Mln

THOMSON REUTERS
·
Nov 05

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Nov 05

Recursion Pharmaceuticals Names Najat Khan as CEO

Reuters
·
Nov 05

Recursion Pharmaceuticals Inc - Najat Khan to Succeed Chris Gibson as CEO

THOMSON REUTERS
·
Nov 05